EyePoint Pharmaceuticals Inc. buy Royal Bank of Canada
Start price
17.06.25
/
50%
€8.18
Target price
17.06.26
€24.24
Performance (%)
89.23%
Price
04.03.26
€15.09
Summary
This prediction is currently active. With a performance of 89.23% the BUY prediction by Royal_Bank_of_Canada is a big success. This prediction currently runs until 17.06.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| EyePoint Pharmaceuticals Inc. | 9.227% | 9.227% |
| iShares Core DAX® | -3,81 % | -1,47 % |
| iShares Nasdaq 100 | 0,49 % | 2,21 % |
| iShares Nikkei 225® | -4,42 % | 4,97 % |
| iShares S&P 500 | 0,25 % | 1,23 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.59
06.11.25
06.11.25
€33.89
06.11.26
06.11.26
61.33%
04.03.26
04.03.26

